TransMedics Group Inc

TransMedics Group, Inc. (NASDAQ: TMDX) is a commercial-stage medical technology company that is disrupting the organ transplant industry by replacing traditional "cold storage" with a system that mimics the human body's natural state.

As per our previous US Daily Report published on ‘TMDX’ on February 15, 2026, we provided a ‘Speculative Buy’ stance on the stock at USD 129.84 based on “price action, the stock’s current price levels forming a symmetrical triangle pattern during a rally, and momentum oscillator analysis” and the stock price has now moved up by ~11.88% since then and attained resistance 1 and moving towards resistance 2.

Noted below are the details of support and resistance levels provided in our previous report:

Daily Chart

Considering moderation in revenue growth guidance for 2026 (20–25% vs 37% in FY2025), margin pressure from continued investment in R&D and NOP logistics expansion, reliance on a one-time USD 103.3 million tax valuation allowance release that materially inflated FY2025 net income (USD 190.3 million), and execution risks associated with European NOP rollout and new OCS Kidney commercialization despite strong 32% Q4 revenue growth and expanding OCS case volumes (5,139 cases, +38%), a ‘Sell’ rating is assigned to the ‘TMDX’ at the closing market price of USD 145.26, as of February 27, 2026.

Note: This report may be updated with details around fundamental and technical analysis, price chart in due course, as appropriate.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is February 27, 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.